Reactions 1704, p177 - 2 Jun 2018 Hypercholesterolaemia and dyslipidaemia: case report In a study of 5 patients, one patient [age and sex not stated] was described, who developed hypercholesterolaemia and dyslipidaemia during treatment with haloperidol [Haldol; dosage not stated] for schizophrenia. The patient, who had schizophrenia, started receiving treatment with antipsychotic long-acting injections, which included haloperidol depot once a month with fluphenazine. The patient developed metabolic side effects, which included hypercholesterolaemia and dyslipidaemia secondary to haloperidol [duration of treatment to reaction onsets and outcomes not stated]. Author comment: "In one patient treated with haloperidol, metabolic side effects such as hypercholesterolaemia and dyslipidaemia were observed." Rankovic A, et al. Problems with the Administration of Antipsychotic Drugs in Depot Formulations in the Treatment of Schizophrenia. Acta Facultatis Medicae Naissensis 35: 65-72, No. 1, Mar 2018. Available from: URL: http:// doi.org/10.2478/afmnai-2018-0007 - Serbia 803323299 0114-9954/18/1704-0001/$14.95 Adis © 2018 Springer International Publishing AG. All rights reserved Reactions 2 Jun 2018 No. 1704
Reactions Weekly – Springer Journals
Published: Jun 2, 2018
It’s your single place to instantly
discover and read the research
that matters to you.
Enjoy affordable access to
over 18 million articles from more than
15,000 peer-reviewed journals.
All for just $49/month
Query the DeepDyve database, plus search all of PubMed and Google Scholar seamlessly
Save any article or search result from DeepDyve, PubMed, and Google Scholar... all in one place.
All the latest content is available, no embargo periods.
“Whoa! It’s like Spotify but for academic articles.”@Phil_Robichaud